TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9624783

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg once daily for 7 days
Number of subjects: 272

Group type: COMPARATOR
Intervention: Oral ciprofloxacin 500 mg twice daily for 10 days
Number of subjects: 272
Study: 7837834

Group type: EXPERIMENTAL
Intervention: Zemide 20 (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available tablet formulation (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Number of subjects: 12
Study: 3341391

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 47
Study: 31424957

Group type: EXPERIMENTAL
Intervention: TUNEL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PCNA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SOX2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Apoptosis rates
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Proliferation rates
Number of subjects: 50
Study: 31075683

Group type: EXPERIMENTAL
Intervention: Early MS group (N = 24)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Late MS group (N = 45)
Number of subjects: 69
Study: 27777128

Group type: EXPERIMENTAL
Intervention: Learning about Activity and Understanding Nutrition for Child Health (LAUNCH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational-interviewing intervention (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (STC)
Number of subjects: 0
Study: 26814847

Group type: EXPERIMENTAL
Intervention: TwHF based therapy in predictor positive (P+) group
Number of subjects: 167

Group type: COMPARATOR
Intervention: TwHF based therapy in predictor negative (P-) group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Methotrexate and Sulfasalazine combination therapy (M) in predictor positive (P+) group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Methotrexate and Sulfasalazine combination therapy (M) in predictor negative (P-) group
Number of subjects: 167
Study: 23754758

Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 1 (3% mortality and MI)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 4 (14% mortality and MI)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 1 (1% cardiovascular death and MI)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 4 (11% cardiovascular death and MI)
Number of subjects: 320
Study: 21472664

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Colestimide
Number of subjects: 48
Study: 19246522

Group type: EXPERIMENTAL
Intervention: Enrolled patients at the lead site (n = 27)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Eligible nonenrolled patients at the lead site (n = 70)
Number of subjects: 97
Study: 16978844

Group type: EXPERIMENTAL
Intervention: Triple therapy plus probiotic food (250 mL of yogurt containing Bifidobacterium animalis and Lactobacillus casei at 10^7 CFU/mL) for 1 week and administered for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Milk placebo
Number of subjects: 65
Study: 15343566

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 106

Group type: COMPARATOR
Intervention: Balloon angioplasty plus cilostazol (200 mg/day for 6 months)
Number of subjects: 106
Study: 10937764

Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg I/ml)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Iohexol (350 mg I/ml)
Number of subjects: 119
Study: 9080918

Group type: EXPERIMENTAL
Intervention: acebutolol (n = 132)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: chlorthalidone (n = 126)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: amlodipine maleate (n = 131)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: doxazosin mesylate (n = 134)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: enalapril maleate (n = 135)
Number of subjects: 902

Group type: COMPARATOR
Intervention: placebo (n = 234)
Number of subjects: 902
Study: 7920926

Group type: EXPERIMENTAL
Intervention: IVF with transfer on day 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfers of frozen-thawed blastocysts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coculture
Number of subjects: 0
Study: 30896297

Group type: EXPERIMENTAL
Intervention: Insomnia Catastrophizing Scale (ICS) - nighttime catastrophizing subscale (11 items)
Number of subjects: 1615

Group type: EXPERIMENTAL
Intervention: Insomnia Catastrophizing Scale (ICS) - daytime catastrophizing subscale (6 items)
Number of subjects: 1615

Group type: COMPARATOR
Intervention: Insomnia disorder group
Number of subjects: 1615

Group type: EXPERIMENTAL
Intervention: ICS subscales
Number of subjects: 1615
Study: 30485450

Group type: EXPERIMENTAL
Intervention: Sanguisorba officinalis root extract
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 21
Study: 27802242

Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26314432

Group type: EXPERIMENTAL
Intervention: Arsenous acid (H3AsO3) treatment
Number of subjects: 86
Study: 23791261

Group type: EXPERIMENTAL
Intervention: Twisted File (TF) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: WaveOne (WO) system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both TF and WO systems
Number of subjects: 40
Study: 21391828

Group type: EXPERIMENTAL
Intervention: Peer health workers (PHWs) providing care; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (conventional clinical staff); specific details not mentioned.
Number of subjects: 0
Study: 17929164

Group type: EXPERIMENTAL
Intervention: Piracetam + risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + risperidone
Number of subjects: 40
Study: 16673283

Group type: EXPERIMENTAL
Intervention: Medical Research Council Primary Thrombocythemia 1 trial (MRC PT‐1)
Number of subjects: 0
Study: 12912807

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins C (500 mg/d) and E (400 IU/d) for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study: 10924426

Group type: EXPERIMENTAL
Intervention: Photoelectric alarms (58 homes)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Ionization alarms (65 homes)
Number of subjects: 123
Study: 8669567

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 1997932

Group type: EXPERIMENTAL
Intervention: MTC + L (metoclopramide 1 mg/kg or 0.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Number of subjects: 100

Group type: COMPARATOR
Intervention: ALZ + L (alizapride 3 mg/kg or 1.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MTC + L
Number of subjects: 100

Group type: COMPARATOR
Intervention: ALZ + L
Number of subjects: 100
Study: 6342461

Group type: EXPERIMENTAL
Intervention: Buprenorphine (5, 10, and 15 micrograms/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fentanyl (10 micrograms/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 71
Study: 31404221

Group type: EXPERIMENTAL
Intervention: Open abdomen management with negative-peritoneal-pressure therapy (NPPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formal abdominal closure
Number of subjects: 0
Study: 30153752

Group type: EXPERIMENTAL
Intervention: Ketamine plus placebo (0.5 mg/kg of ketamine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine plus naltrexone (50 mg of naltrexone preceding ketamine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine plus naltrexone
Number of subjects: 30
Study: 27117852

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: NAC + Vitamin C
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 24755206

Group type: EXPERIMENTAL
Intervention: Peer-led self-management education
Number of subjects: 404

Group type: COMPARATOR
Intervention: Professionally delivered self-management education (seminar posts)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Both groups (peer-led and seminar posts)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Participants with uncontrolled BP at baseline
Number of subjects: 404
Study: 23158714

Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Univent blocker (UNI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Coopdech bronchial blocker (BB)
Number of subjects: 120
Study: 19022621

Group type: EXPERIMENTAL
Intervention: Contrast echocardiography (CE) performed in the standing position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Contrast echocardiography (CE) performed in the supine position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard echocardiographic parameters
Number of subjects: 50
Study: 17600655

Group type: EXPERIMENTAL
Intervention: Endovenous laser (EVL) ablation of the great saphenous vein (980 nm)
Number of subjects: 121

Group type: COMPARATOR
Intervention: High ligation and stripping (HL/S)
Number of subjects: 121
Study: 15353973

Group type: EXPERIMENTAL
Intervention: Low-dose Vacc-4x
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose Vacc-4x
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HLA-A2 negative patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: HLA-A2 positive patients
Number of subjects: 40
Study: 11593469

Group type: EXPERIMENTAL
Intervention: N(2)O/O(2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: O(2)
Number of subjects: 10
Study: 9870830

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary case management program
Number of subjects: 437

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 437
Study: 8066111

Group type: EXPERIMENTAL
Intervention: Stretching for 15 seconds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stretching for 30 seconds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stretching for 60 seconds
Number of subjects: 57

Group type: COMPARATOR
Intervention: No stretching (Control)
Number of subjects: 57
Study: 2543939

Group type: EXPERIMENTAL
Intervention: Müzli prepared from dry fruits and rough ground grain flakes of rich ballast material content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional food of poor roughage content
Number of subjects: 0
Study: 31005318

Group type: EXPERIMENTAL
Intervention: Weaned by intake (successful-intake group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weaned by intake (early weaning)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weaned by age
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weaned by intake (late weaning)
Number of subjects: 64
Study: 27940188

Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention (PSI) during OAT
Number of subjects: 368

Group type: COMPARATOR
Intervention: Opioid agonist treatment-as-usual
Number of subjects: 368
Study: 25370889

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg daily for 56 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (days 1-28) followed by Armodafinil 150 mg daily (days 29-56)
Number of subjects: 0
Study: 23818981

Group type: EXPERIMENTAL
Intervention: High viscosity (HV) semi‐solid meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard viscosity (SV) semi‐solid meal
Number of subjects: 15
Study: 22462234

Group type: EXPERIMENTAL
Intervention: Guo's Ma Qian Decoction, initial dose 0.4 g, increased by 0.05 g every two days, max 1.2 g/day.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Decoction placebo (control group).
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Guo's Ma Qian Decoction, blood strychnine and brucine levels.
Number of subjects: 114
Study: 19436136

Group type: EXPERIMENTAL
Intervention: VKORC1 rs8050894 GG homozygotes
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: VKORC1 rs7294 AA or AG carriers
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: GGCX rs10187424 and rs7568458 heterozygous carriers
Number of subjects: 416
Study: 16446336

Group type: EXPERIMENTAL
Intervention: CVI fluorouracil (FU) 225 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid (arm 1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CVI FU 225 mg/m2 per day Monday to Friday, 120 hours per week plus irinotecan 50 mg/m2 once weekly for 4 weeks plus pelvic radiation therapy 50.4 to 54 Gy at 1.8 Gy per day (arm 2)
Number of subjects: 106
Study: 12844212

Group type: EXPERIMENTAL
Intervention: Exercise (supervised aerobic, weight‐bearing and weight‐lifting exercise, three times per week) with calcium supplementation (800 mg daily)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Exercise (with calcium supplementation)
Number of subjects: 320

Group type: COMPARATOR
Intervention: No exercise (with calcium supplementation)
Number of subjects: 320
Study: 10993791

Group type: EXPERIMENTAL
Intervention: Fixed-rate atrial pacing at multiple cycle lengths (CLs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atrial pacing with isoproterenol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher heart rate (HR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moderate elevation of HR
Number of subjects: 24
Study: 8996468

Group type: EXPERIMENTAL
Intervention: Tenidap (40-200 mg/day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 1282537

Group type: EXPERIMENTAL
Intervention: Warfarin (traditional and low-dose regimens)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Aspirin (three groups)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Dextran
Number of subjects: 855

Group type: COMPARATOR
Intervention: External pneumatic compression
Number of subjects: 855

Group type: COMPARATOR
Intervention: Dextran combined with external pneumatic compression
Number of subjects: 855
Study: 3905183

Group type: EXPERIMENTAL
Intervention: Auto‐Syringe AS 6C (basal rate in pulses every 2‐10 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Medix Syringe Driver 209 (basal rate in pulses every 15‐60 min)
Number of subjects: 6
Study: 30462837

Group type: EXPERIMENTAL
Intervention: Active Working Memory (WM) training for 5 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Active Working Memory (WM) training
Number of subjects: 50
Study: 31034598

Group type: EXPERIMENTAL
Intervention: ontuxizumab (8 mg/kg) plus gemcitabine and docetaxel (G/D)
Number of subjects: 209

Group type: COMPARATOR
Intervention: placebo plus gemcitabine and docetaxel (G/D)
Number of subjects: 209
Study: 27823901

Group type: EXPERIMENTAL
Intervention: Eccentric-concentric training combined with isometric contraction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Eccentric training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Eccentric-concentric training
Number of subjects: 34
Study: 24947675

Group type: EXPERIMENTAL
Intervention: Oxycodone orodispersible tablet (OOT) 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paracetamol orodispersible tablet (POT) 500 mg
Number of subjects: 12
Study: 23375525

Group type: EXPERIMENTAL
Intervention: 1.8 g/d of ω‐3 PUFA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.6 g/d of ω‐3 PUFA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 21410828

Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen (CEE) 0.625 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen (CEE) 0.625 mg/day plus Medroxyprogesterone Acetate (MPA) 2.5 mg/day
Number of subjects: 75
Study: 19270449

Group type: EXPERIMENTAL
Intervention: 12 mg/kg intravenous mesna administered predialysis for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered predialysis for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 mg/kg intravenous mesna administered predialysis for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered predialysis for 4 weeks
Number of subjects: 0
Study: 17416878

Group type: EXPERIMENTAL
Intervention: Chronic care model approach to injury prevention; Intervention details: Focused counseling from a physician and health assistant, educational handouts, phone follow-up, access to free safety devices and automobile restraint evaluations.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard anticipatory guidance; Control group: Yes
Number of subjects: 27
Study: 15254053

Group type: EXPERIMENTAL
Intervention: Arm 1: Cisplatin 10 mg/m² daily and fluorouracil (FU) 400 mg/m² continuous infusion (CI) daily for the final 10 days of treatment
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Arm 2: Hydroxyurea 1 g every 12 hours and FU 800 mg/m²/d CI delivered with each fraction of radiation
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Arm 3: Weekly paclitaxel 30 mg/m² and cisplatin 20 mg/m²
Number of subjects: 231
Study: 12027068

Group type: EXPERIMENTAL
Intervention: Albuterol HFA (180 microg ex-actuator)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Albuterol CFC (180 microg ex-actuator)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo HFA
Number of subjects: 24
Study: 9824345

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound evaluation of splanchnic haemodynamics in Crohn's disease
Number of subjects: 79

Group type: COMPARATOR
Intervention: Doppler ultrasound evaluation of splanchnic haemodynamics in controls
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Assessment of splanchnic haemodynamics
Number of subjects: 79
Study: 7973478

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone hexacetonide (TA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 330 mg sodium morrhuate (SM)
Number of subjects: 31
Study: 2532184

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (150 micrograms/day for 4 weeks)
Number of subjects: 20
Study: 31377306

Group type: EXPERIMENTAL
Intervention: Clinical Pilates training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Home exercise training
Number of subjects: 42
Study: 30823900

Group type: EXPERIMENTAL
Intervention: Educational outreach visits
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Quality indicators adherence
Number of subjects: 426
Study: 27810290

Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: TIMI score
Number of subjects: 1748
Study: 26297701

Group type: EXPERIMENTAL
Intervention: Mixed low-resistance training (LOW+, 1 × 60 repetitions at 20% 1 RM followed by 1 × 10-20 repetitions at 40% 1 RM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: High-resistance training (HIGH, 2 × 10-15 repetitions at 80% 1 RM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-resistance training (LOW, 1 × 80-100 repetitions at 20% 1 RM)
Number of subjects: 56
Study: 23833916

Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 118

Group type: COMPARATOR
Intervention: Negative control dentifrice (1,000 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 118
Study: 21354234

Group type: EXPERIMENTAL
Intervention: Danoprevir/r (100/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danoprevir/r (200/100mg once daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danoprevir/r (200/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo/r plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 30
Study: 18506466

Group type: EXPERIMENTAL
Intervention: Liquid alginate suspension (Gaviscon Advance) 10 ml four times daily after meals and at bedtime
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study: 16290918

Group type: EXPERIMENTAL
Intervention: Decision-support tools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15330693

Group type: EXPERIMENTAL
Intervention: Active home stretching
Number of subjects: 33

Group type: COMPARATOR
Intervention: Passive home stretching
Number of subjects: 33
Study: 10768064

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate (3.1 g every 4 or 6 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate with amikacin (when pneumonia was due to Pseudomonas aeruginosa)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate
Number of subjects: 11
Study: 9260072

Group type: EXPERIMENTAL
Intervention: Immediate, informative monetary consequence (MI) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delayed, uninformative monetary consequence (M) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No consequence (N) under moderate dose of alcohol (0.62 g/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C) performed the task without alcohol or any consequence
Number of subjects: 40
Study: 7678061

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU in the cardiopulmonary bypass priming solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 30
Study: 7073920

Group type: EXPERIMENTAL
Intervention: Midazolam (0.30 mg kg‐1 i.v.)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 194
Study: 31260526

Group type: EXPERIMENTAL
Intervention: AFEX-treated wheat straw
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enzymes (500 µg of protein/g straw DM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enzymes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated wheat straw
Number of subjects: 16
Study: 29156903

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (single 8 Gy radiation treatment)
Number of subjects: 298